摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-(pyrazin-2-ylamino)-pyridin-4-ylmethyl]-1H-indol-4-ylamine | 1044717-93-2

中文名称
——
中文别名
——
英文名称
1-[2-(pyrazin-2-ylamino)-pyridin-4-ylmethyl]-1H-indol-4-ylamine
英文别名
1-[[2-(pyrazin-2-ylamino)pyridin-4-yl]methyl]indol-4-amine
1-[2-(pyrazin-2-ylamino)-pyridin-4-ylmethyl]-1H-indol-4-ylamine化学式
CAS
1044717-93-2
化学式
C18H16N6
mdl
——
分子量
316.365
InChiKey
DWAKGLZEDYTPJV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    81.6
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Certain substituted ureas as modulators of kinase activity
    申请人:Mitchell A. Scott
    公开号:US20060199846A1
    公开(公告)日:2006-09-07
    Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.
    本文提供了从式1化合物中选择的某些化学实体及其药学可接受的盐、溶剂化物、晶体形式、螯合物、非共价复合物、前药和混合物。本文还提供了包含至少一种化学实体和一种或多种药学可接受的载体、佐剂和赋形剂的制药组合物。本文还揭示了用于治疗对血管生成激酶调节有反应的某些疾病和障碍的患者的方法,包括向这些患者施用足够量的至少一种化学实体,以减少疾病或障碍的症状或体征。这些疾病包括癌症,包括乳腺肿瘤、子宫内膜癌、结肠癌和颈部鳞状细胞癌。治疗方法包括将至少一种化学实体作为单一活性剂施用或与一种或多种其他治疗剂联合使用。本文还揭示了一种用于确定样品中是否存在血管生成激酶的方法,包括在允许检测血管生成激酶活性的条件下,将样品与至少一种化学实体接触,检测血管生成激酶活性水平,并从中确定样品中是否存在血管生成激酶。
  • 1,3-diaryl substituted ureas as modulators of kinase activity.
    申请人:CGI Pharmaceuticals, Inc.
    公开号:EP2397478A1
    公开(公告)日:2011-12-21
    Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Use in treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, or detecting a level of the activity of the angiogenic kinase.
    选自式 1 化合物的某些化学实体 及其药学上可接受的盐、溶液、晶体、螯合物、非共价复合物、原药和混合物。本文还提供了由至少一种化学实体和一种或多种药学上可接受的载体(选自载体、佐剂和赋形剂)组成的药物组合物。公开了用于治疗对血管生成激酶调节有反应的某些疾病和失调患者的方法,其中包括向此类患者施用有效减少疾病或失调的体征或症状的至少一种化学实体。这些疾病包括癌症,包括乳腺癌、子宫内膜癌、结肠癌和颈部鳞状细胞癌。一种确定样品中是否存在血管生成激酶的方法,包括在允许检测血管生成激酶活性的条件下将样品与至少一种化学物质接触,或检测血管生成激酶的活性水平。
  • 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY
    申请人:CGI Pharmaceuticals, Inc.
    公开号:EP1858879A1
    公开(公告)日:2007-11-28
  • [EN] 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY<br/>[FR] UREES A SUBSTITUTION 1,3-DIARYLE, MODULATEURS DE L'ACTIVITE DE KINASES
    申请人:CGI PHARMACEUTICALS INC
    公开号:WO2006076593A1
    公开(公告)日:2006-07-20
    [EN] Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Use in treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck sguamous cell carcinoma. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom
    [FR] L'invention porte: sur certaines entités chimiques de formule (I) et leurs sels, solvates, formes cristallines, chélates, complexes non covalents, prodrogues, pharmacocompatibles, et leurs mélanges; sur des préparations pharmaceutiques comprenant au moins l'une de ces entités et un ou des véhicules choisis parmi des vecteurs, adjuvants et excipients; sur leur utilisation pour traiter des patients souffrant de maladies ou troubles réagissant à la modulation de la kinase angiogène tels que des cancers, dont ceux du sein, de l'endomètre, du colon, et le carcinome squameux du col, consistant à leur administrer une dose d'au moins une de ces entités pour en réduire les signes ou les symptômes; et sur une méthode permettant de déterminer la présence ou l'absence d'une kinase angiogène dans un échantillon, consistant à mettre l'échantillon en contact avec l'une au moins desdites entités dans des conditions permettant de détecter l'activité de ladite kinase et son niveau.
  • WO2006/76593
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多

同类化合物

(Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (R)-(+)-5'-苄氧基卡维地洛 (R)-卡洛芬 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (3Z)-3-(1H-咪唑-5-基亚甲基)-5-甲氧基-1H-吲哚-2-酮 (3Z)-3-[[[4-(二甲基氨基)苯基]亚甲基]-1H-吲哚-2-酮 (3R)-(-)-3-(1-甲基吲哚-3-基)丁酸甲酯 (3-氯-4,5-二氢-1,2-恶唑-5-基)(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)乙酸 齐多美辛 鸭脚树叶碱 鸭脚木碱,鸡骨常山碱 鲜麦得新糖 高氯酸1,1’-二(十六烷基)-3,3,3’,3’-四甲基吲哚碳菁 马鲁司特 马来酸阿洛司琼 马来酸替加色罗 顺式-ent-他达拉非 顺式-1,3,4,4a,5,9b-六氢-2H-吡啶并[4,3-b]吲哚-2-甲酸乙酯 顺式-(+-)-3,4-二氢-8-氯-4'-甲基-4-(甲基氨基)-螺(苯并(cd)吲哚-5(1H),2'(5'H)-呋喃)-5'-酮 靛红联二甲酚 靛红磺酸钠 靛红磺酸 靛红乙烯硫代缩酮 靛红-7-甲酸甲酯 靛红-5-磺酸钠 靛红-5-磺酸 靛红-5-硫酸钠盐二水 靛红-5-甲酸甲酯 靛红 靛玉红3'-单肟5-磺酸 靛玉红-3'-单肟 靛玉红 青色素3联己酸染料,钾盐 雷马曲班 雷莫司琼杂质13 雷莫司琼杂质12 雷莫司琼杂质 雷替尼卜定 雄甾-1,4-二烯-3,17-二酮 阿霉素的代谢产物盐酸盐 阿贝卡尔 阿西美辛叔丁基酯 阿西美辛 阿莫曲普坦杂质1 阿莫曲普坦 阿莫曲坦二聚体杂质 阿莫曲坦 阿洛司琼杂质